BR0307410A - Uso de inibidores de pde5 no tratamento da cicatrização e fibrose - Google Patents

Uso de inibidores de pde5 no tratamento da cicatrização e fibrose

Info

Publication number
BR0307410A
BR0307410A BR0307410-2A BR0307410A BR0307410A BR 0307410 A BR0307410 A BR 0307410A BR 0307410 A BR0307410 A BR 0307410A BR 0307410 A BR0307410 A BR 0307410A
Authority
BR
Brazil
Prior art keywords
fibrosis
treatment
healing
inhibitors
pde5 inhibitors
Prior art date
Application number
BR0307410-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Richard Philip Butt
Stephen Charles Phillips
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR0307410A publication Critical patent/BR0307410A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR0307410-2A 2002-01-31 2003-01-21 Uso de inibidores de pde5 no tratamento da cicatrização e fibrose BR0307410A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202254.9A GB0202254D0 (en) 2002-01-31 2002-01-31 Prevention of scarring
PCT/IB2003/000134 WO2003063875A1 (en) 2002-01-31 2003-01-21 Use of pde5 inhibitors in the treatment of scarring and fibrosis

Publications (1)

Publication Number Publication Date
BR0307410A true BR0307410A (pt) 2004-12-28

Family

ID=9930135

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307410-2A BR0307410A (pt) 2002-01-31 2003-01-21 Uso de inibidores de pde5 no tratamento da cicatrização e fibrose

Country Status (8)

Country Link
EP (1) EP1469857A1 (https=)
JP (1) JP2005523263A (https=)
BR (1) BR0307410A (https=)
CA (1) CA2474852A1 (https=)
GB (1) GB0202254D0 (https=)
MX (1) MXPA04007430A (https=)
TW (1) TW200302105A (https=)
WO (1) WO2003063875A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2525946C (en) * 2003-05-22 2013-01-29 Altana Pharma Ag Composition comprising a pde4 inhibitor and a pde5 inhibitor
CN101106997A (zh) 2004-08-17 2008-01-16 约翰·霍普金斯大学 Pde5抑制剂组合物及治疗心脏病征候的方法
US8268785B2 (en) 2004-08-19 2012-09-18 Switch Biotech Ag Use of a Pde 5 inhibitor for treating and preventing hypopigmentary disorders
EP1759700B1 (en) * 2004-08-19 2009-08-05 Switch Biotech, LLC Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders
WO2006074443A2 (en) * 2005-01-07 2006-07-13 The Johns Hopkins University Pde5 inhibitor compositions and methods for immunotherapy
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
US20090215782A1 (en) * 2005-04-18 2009-08-27 Carlo Foresta Use of PDE-5 Inhibitors for Endothelial Repair of Tissues Impaired by Trauma or Disease
PT1888074E (pt) 2005-06-10 2012-03-01 Dong A Pharm Co Ltd Agente para a prevenção e tratamento de doenças do fígado contendo um derivado de pirazolopirimidina
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
JP2013523809A (ja) * 2010-04-05 2013-06-17 エスケー ケミカルズ カンパニー リミテッド Ｐｄｅ５抑制剤を含む皮膚しわ改善用組成物
HRP20150987T1 (hr) 2010-05-26 2015-10-23 Adverio Pharma Gmbh UPORABA sGC STIMULATORA, sGC AKTIVATORA, SAMOSTALNO I U KOMBINACIJAMA S INHIBITORIMA PDE5 ZA LIJEÄŚENJE SISTEMSKE SKLEROZE (SSc)
JP2014526461A (ja) * 2011-09-09 2014-10-06 エスケー ケミカルズ カンパニー，リミテッド Ｐｄｅ５抑制剤を含む皮膚しわ改善用組成物
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
ES2882258T3 (es) 2012-12-21 2021-12-01 Mayo Found Medical Education & Res Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
EP2992885A3 (en) * 2014-09-02 2016-05-18 Jansfat Biotechnology Co., Ltd. Method for inhibiting a liver disease
CA3055882A1 (en) 2017-03-14 2018-09-20 Atir Holding S.A. Topical formulation for the treatment of pigmented skin
EP4166129A1 (en) 2017-03-14 2023-04-19 Atir Holding S.A. Use of heterocyclic compounds in the treatment of aged skin
MX2017016930A (es) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico.
KR20210150495A (ko) 2019-04-10 2021-12-10 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 심혈관 기능장애의 성별-의존적 치료를 위한 방법 및 재료
CN112773898A (zh) * 2019-11-11 2021-05-11 广州华真医药科技有限公司 磷酸二酯酶5抑制剂在制备抗纤维化疾病药物中的应用
AU2022325803A1 (en) * 2021-08-13 2024-03-28 Goldberg, David J. Methods and compositions for treating fibrotic liver conditions, using udenafil compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5965501A (en) * 1997-03-28 1999-10-12 Lever Brothers Company, Division Of Conopco, Inc. Personal washing bar compositions comprising emollient rich phase/stripe
WO1999026946A1 (en) * 1997-11-26 1999-06-03 Mochida Pharmaceutical Co., Ltd. PYRIDOCARBAZOLE DERIVATIVES WITH cGMP-PDE INHIBITORY ACTIVITY
ZA9810766B (en) * 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity
GB9909135D0 (en) * 1999-04-22 1999-06-16 Univ Wales Medicine Cystic fibrosis medicaments
US6503908B1 (en) * 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy

Also Published As

Publication number Publication date
TW200302105A (en) 2003-08-01
MXPA04007430A (es) 2005-06-20
WO2003063875A1 (en) 2003-08-07
CA2474852A1 (en) 2003-08-07
JP2005523263A (ja) 2005-08-04
GB0202254D0 (en) 2002-03-20
EP1469857A1 (en) 2004-10-27

Similar Documents

Publication Publication Date Title
BR0307410A (pt) Uso de inibidores de pde5 no tratamento da cicatrização e fibrose
CY1105390T1 (el) Θepαπευτικη αγωγη της πνευμονικης υπερτασης
MXPA05013637A (es) Inhibidores gsk-3 y usos de los mismos.
DK1636236T3 (da) Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer
NO20075099L (no) Alkynyl-pyrrolopyrmidiner og relaterte analoger som HSP90-inhibitorer
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
EP1129706A3 (en) Use of cGMP PDE5 inhibitors for the treatment of neuropathy
NO20051647L (no) Pyrazolopyrimidiner som syklinavhengige kinaseinhibitorer
NO20064584L (no) Tetrahydropyridoindolderivater
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
BRPI0406796A (pt) Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina
MXPA04005809A (es) Inhibidores de proteinas quinasas.
ZA200205694B (en) Treatment of diabetic ulcers.
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
BRPI0411168B1 (pt) Composição para o tratamento dos cabelos, usos da composição e método de tratamento dos cabelos.
BR0111785A (pt) Composições e métodos para tratamento de candidìase
BR0115413A (pt) Tratamento de ejaculação precoce
BRPI0509667A (pt) azaquinazolinas substituìdas com eficácia antiviral
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
NO20062229L (no) Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er)
EP1465616A4 (en) TREATMENT OF SIDE EFFECTS OF STATINE USING URIDINE DERIVATIVES
AU2003298244A8 (en) Method for inhibiting the replication of herpes viruses
UA38352A (uk) Засіб для лікувальних ванн

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 8A E 9A ANUIDADE(S).

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 8A E 9A ANUIDADES.